The generic drugs cost a fourth as much as their name-brand counterparts, a price that would make them available to many more of the 30-million Africans with Aids.
They are being pushed hard by the WHO and various Aids activist groups. But makers of brand-name pharmaceuticals, already fighting a global flood of attempts to copy their patented treatments, strongly oppose their use –in part, they say, for safety reasons.
EMAIL THIS ARTICLE SAVE THIS ARTICLE FEEDBACK
To subscribe email subscriptions@creamermedia.co.za or click here
To advertise email advertising@creamermedia.co.za or click here
